S&P 500   4,410.13 (+0.28%)
DOW   34,364.50 (+0.29%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
S&P 500   4,410.13 (+0.28%)
DOW   34,364.50 (+0.29%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
S&P 500   4,410.13 (+0.28%)
DOW   34,364.50 (+0.29%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
S&P 500   4,410.13 (+0.28%)
DOW   34,364.50 (+0.29%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
NASDAQ:BLCM

Bellicum Pharmaceuticals Stock Forecast, Price & News

$1.44
-0.01 (-0.69%)
(As of 01/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.38
$1.46
50-Day Range
$1.40
$2.08
52-Week Range
$1.38
$8.15
Volume
140,007 shs
Average Volume
55,314 shs
Market Capitalization
$12.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.5
30 days | 90 days | 365 days | Advanced Chart
Receive BLCM News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Bellicum Pharmaceuticals logo

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLCM
Fax
N/A
Employees
16
Year Founded
N/A

Sales & Book Value

Annual Sales
$500 thousand
Book Value
($0.30) per share

Profitability

Net Income
$-7.72 million
Pretax Margin
105.60%

Debt

Price-To-Earnings

Miscellaneous

Free Float
8,170,000
Market Cap
$12.09 million
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
1/24/2022
Next Earnings (Estimated)
3/29/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

0.93 out of 5 stars

Medical Sector

1293rd out of 1,415 stocks

Pharmaceutical Preparations Industry

628th out of 683 stocks

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Bellicum Pharmaceuticals (NASDAQ:BLCM) Frequently Asked Questions

How has Bellicum Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Bellicum Pharmaceuticals' stock was trading at $7.29 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BLCM shares have decreased by 80.2% and is now trading at $1.44.
View which stocks have been most impacted by COVID-19
.

When is Bellicum Pharmaceuticals' next earnings date?

Bellicum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for Bellicum Pharmaceuticals
.

How were Bellicum Pharmaceuticals' earnings last quarter?

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) announced its earnings results on Thursday, November, 4th. The biopharmaceutical company reported $0.07 EPS for the quarter. The biopharmaceutical company had revenue of $5 million for the quarter.
View Bellicum Pharmaceuticals' earnings history
.

When did Bellicum Pharmaceuticals' stock split? How did Bellicum Pharmaceuticals' stock split work?

Shares of Bellicum Pharmaceuticals reverse split on the morning of Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 5th 2020. An investor that had 100 shares of Bellicum Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Who are Bellicum Pharmaceuticals' key executives?

Bellicum Pharmaceuticals' management team includes the following people:
  • Richard A. Fair, President, Chief Executive Officer & Director
  • Aaron Foster, Senior Vice President & Head-Research
  • Joseph Howard Senesac, Vice President-Viral Vector Development

What other stocks do shareholders of Bellicum Pharmaceuticals own?

When did Bellicum Pharmaceuticals IPO?

(BLCM) raised $101 million in an initial public offering on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.

What is Bellicum Pharmaceuticals' stock symbol?

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

How do I buy shares of Bellicum Pharmaceuticals?

Shares of BLCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bellicum Pharmaceuticals' stock price today?

One share of BLCM stock can currently be purchased for approximately $1.44.

How much money does Bellicum Pharmaceuticals make?

Bellicum Pharmaceuticals has a market capitalization of $12.09 million and generates $500 thousand in revenue each year. The biopharmaceutical company earns $-7.72 million in net income (profit) each year or ($0.29) on an earnings per share basis.

How many employees does Bellicum Pharmaceuticals have?

Bellicum Pharmaceuticals employs 16 workers across the globe.

What is Bellicum Pharmaceuticals' official website?

The official website for Bellicum Pharmaceuticals is www.bellicum.com.

Where are Bellicum Pharmaceuticals' headquarters?

Bellicum Pharmaceuticals is headquartered at 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030.

How can I contact Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The biopharmaceutical company can be reached via phone at (832) 384-1100 or via email at [email protected].


This page was last updated on 1/24/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.